FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Novo A/S 2. Date of Event Requiring Statement (Month/Day/Year) 08/12/2014 3. Issuer Name and Ticker or Trading Symbol Otonomy, Inc. [OTIC] (Last) (First) (Middle) TUBORG HAVNEVEJ 19 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) __X__ Other (specify below) SEE REMARKS 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) HELLERUP, G7 2900 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	  (1)	  (1)	Common Stock	439,724 (1)	$ (1)	D	Â
Series C Preferred Stock	  (1)	  (1)	Common Stock	1,131,436 (1)	$ (1)	D	Â
Series D Preferred Stock	  (1)	  (1)	Common Stock	348,041 (1)	$ (1)	D	Â
Series C Preferred Stock Warrant (Right to Buy)	  (2)	08/23/2022	Common Stock	36,405 (2)	$ (2)	D	Â
Series C Preferred Stock Warrant (Right to Buy)	  (2)	01/23/2023	Common Stock	31,854 (2)	$ (2)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Novo A/S TUBORG HAVNEVEJ 19 HELLERUP, G7 2900	Â	  X	Â	SEE REMARKS

Signatures

/s/ Thorkil Kastberg Christensen, Chief Financial Officer of Novo A/S		08/12/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Series B, Series C and Series D Preferred Stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock will automatically convert on a one-for-one basis for no additional consideration into the Issuer's common stock. The number of shares reported on this line item reflect the approximate number of shares of the Issuer's common stock subsequent to the 35.16-for-1 reverse split of common stock (the "Stock Split") effected by the Issuer on July 31, 2014.
(2)	Immediately prior to the IPO Closing, the warrants will be exercised for shares of Series C Preferred Stock at an exercise price of $8.79 per share (after adjustment for the Stock Split) (the "Series C Shares"). The Series C Shares will automatically converted upon the IPO Closing on a one-for-one basis for no additional consideration into the Issuer's common stock. The number of shares indicated for this line item represents the approximate number of shares of the Issuer's common stock covered by the warrants and the subsequent conversion of such warrants into the Series C Shares (as adjusted for the Stock Split).
  Remarks: Novo A/S is a Danish limited liability company.  The board of directors of Novo A/S (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board.  As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.